

Safety Data Sheet

Megestrol Acetate Oral Suspension 625mg/5ml (125mg/ml)

SECTION 1 IDENTIFICATION

Product identifier Megestrol Acetate Oral Suspension 625mg/5ml (125mg/ml)

other means of identification NDC No.: 24979-041-13

Recommended use Indicated for the treatment of anorexia, cachexia, or an unexplained, significant

weight loss in patients with a diagnosis of acquired immunodeficiency

syndrome (AIDS)

Manufacturer

Company name TWi Pharmaceuticals, Inc.

Address 3F, No 41, Lane 221, Kang Chien Rd, Taipei, Taiwan.

Telephone 886-2-26573350 **Fax** 886-2-26573391

E-mail address QA.Service@twipharma.com

Emergency phone number 1-844-518-2989

SECTION 2 HAZARD IDENTIFICATION

Physical hazards Not classified.

Health hazards Carcinogenicity: Category 2

Label element

Code H351 Signal word Warning

Pictogram

Hazard statement Suspected of causing cancer.

This is a pharmaceutical product designed to be prescribed by a licensed health care professional. Should any person while using this product observe any

adverse health effects, seek medical treatment.

Precautionary statement

Prevention Observe good industrial hygiene practices. Do not handle until all safety

precautions have been read and understood. Wear protective gloves/protective

clothing/eye protection/face protection.

Response Wash hands after handling. If exposed or concerned: Get medical

advice/attention.

Storage Store at 20 - 25 °C (68 - 77°F). Store away from heat. Store away from

incompatible materials.

Disposal Dispose of contents/container in accordance with

local/regional/national/international regulations. Incineration of waste at an

approved USEPA incinerator is recommended.

Hazard(s) not otherwise

classified (HNOC)

None known.

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml)

Version No.: 02

Issue Date: March 25, 2016 Superseded No.: 01 Safety Data Sheet

Page 1 of 6

SECTION 3 COMPOSITION/INFORMATION ON INGREDIENTS

Product/mixture name Megestrol Acetate Oral Suspension 625mg/5ml (125mg/ml)

Active ingredient:

Chemical Name	Common name/Synonyms	CAS number	%
Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-	Megestrol Acetate	595-33-5	125mg/ml

SECTION 4 FIRST-AID MEASURES

Instructions by routes of exposure

Inhalation Move to fresh air. Call a physician if symptoms develop or persist.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and

persists.

Eye contact Wash with water. Get medical attention if irritation develops and persists.

Wash out mouth. Get medical attention if symptoms occur. **Ingestion**

Most important symptoms/ effects, both acute and delayed The common side effects are weight gain, headache, abdominal pain, diarrhea,

nausea, cough, chest pain.

Immediate medical attention and special treatment

Provide general supportive measures and treat symptomatically. Ensure that medical personnel are aware of the material(s) involved, and take precautions to

Self-contained breathing apparatus and full protective clothing must be worn in

protect themselves.

SECTION 5 FIRE-FIGHTING MEASURES

Suitable extinguishing media Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing media None known

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment

and precautions for firefighters

Firefighting equipment/

case of fire. Move containers from fire area if you can do so without risk.

instructions

General fire hazards No unusual fire or explosion hazards noted.

SECTION 6 ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Wear appropriate personal protective

equipment. Ensure adequate ventilation.

Methods and materials for containment and cleanup

Large Spills: Contain spillage, and then collect with non-combustible absorbent

material, (e.g. sand, earth, diatomaceous earth, vermiculite) and place into

containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface

thoroughly to remove residual contamination.

Environmental precautions Prevent further leakage or spillage and avoid discharge into drains, water

courses or onto the ground.

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml)

Version No.: 02

Issue Date: March 25, 2016 Superseded No.: 01

Safety Data Sheet

Page 2 of 6

SECTION 7 HANDLING AND STORAGE

Precautions for safe handling

Avoid contact with eyes, skin, and clothing and dispense in a tight container.

Conditions for safe storage, including any incompatibilities

Store between 20 to 25 °C (68 - 77°F) Keep away from heat.

SECTION 8 EXPOSURE CONTROLS/PERSONAL PROTECTION

Occupational exposure limits No exposure limits noted for ingredient(s).

Biological limit values No biological exposure limits noted for the ingredient(s).

Appropriate engineering

controls

Ventilation should be matched to conditions.

Individual protection measures, such as personal protective equipment

Eye/face protection None required for consumer use. In laboratory, medical or industrial settings,

safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting.

Contact a health and safety professional for specific information.

Skin protection

Hand protection For consumer use, no unusual precautions are necessary.

Other None required for consumer use. In laboratory, medical or industrial settings,

gloves and lab coats are recommended. The use of additional personal

protective equipment such as shoe coverings, gauntlets, hood or head coverings

may be necessary. Contact a health and safety professional for specific

information.

Respiratory protection None required for consumer use. Respirators may be required for certain

laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a health and safety

professional or manufacturer for specific information.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations Always observe good personal hygiene measures, such as washing after

handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

SECTION 9 PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical state Liquid.

Form Viscous liquid.

Color White to creamy-white

Odor Odorless
Odor threshold Not available.
pH Not available.

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml)

Version No.: 02

Issue Date: March 25, 2016 Superseded No.: 01 **Melting point/freezing point** Not available. **Initial boiling point and boiling** Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or Not available.

explosive limits

Vapor pressureNot available.Vapor densityNot available.Relative densityNot available.

Solubility(ies) Sparingly soluble in alcohol. Slightly soluble in ether and fixed oils. Soluble in

acetone. Very slightly soluble in chloroform.

Partition coefficient:

n-octanol/water

Not available.

Auto-ignition temperatureNot available.Decomposition temperatureNot available.ViscosityNot available.

SECTION 10 STABILITY AND REACTIVITY

Reactivity The product is stable and non-reactive under normal conditions of use, storage

and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

Carbon oxides

SECTION 11 TOXICOLOGICAL INFORMATION

Information on the likely routes of exposure (short-term exposure)

InhalationNot expected to be hazardous in final pharmaceutical form.Skin contactNot expected to be hazardous in final pharmaceutical form.

Eve contact Not expected to be hazardous in final pharmaceutical form. Direct contact with

eyes may cause temporary irritation.

Ingestion Not expected to be hazardous in final pharmaceutical form. May be harmful if

swallowed in large quantities.

Toxicology (long-term exposure)

Symptoms related The common side effects are weight gain, headache, abdominal pain, diarrhea,

nausea, cough, chest pain.

Carcinogenicity Pituitary tumors were observed in rats in long term studies. The relationship of

these tumors in rats to humans is unknown but should be considered in

assessing the risk-to-benefit ratio when prescribing.

In finished product form, risk of occupational exposure is expected to be limited.

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml)

Version No.: 02

Issue Date: March 25, 2016 Superseded No.: 01

IARC Monographs. Overall Evaluation of Carcinogenicity

Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- (CAS 595-33-5)

Category: 2A Probably carcinogenic to humans.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity Pregnancy Category: X There are no adequate animal teratology information

available for clinically relevant doses.

Because of the potential for adverse effects on the newborn, nursing should be

discontinued.

SECTION 12 ECOLOGICAL INFORMATION

Ecotoxicity Could be a potential endocrine disruptor in the environment. Collect and reclaim

or dispose in sealed containers at licensed waste disposal site.

Persistence and degradability Dispose in accordance with all applicable regulations.

Bioaccumulative potential The waste code should be assigned in discussion between the user, the producer

and the waste disposal company.

Mobility in soil Dispose of in accordance with local regulations. Empty containers or liners may

retain some product residues. This material and its container must be disposed

of in a safe manner (see: Disposal instructions).

Other adverse effects Empty containers should be taken to an approved waste handling site for

recycling or disposal. Since emptied containers may retain product residue,

follow label warnings even after container is emptied.

SECTION 13 DISPOSAL CONSIDERATIONS

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal

site.

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste codeThe waste code should be assigned in discussion between the user, the producer

and the waste disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may

retain some product residues. This material and its container must be disposed

of in a safe manner (see: Disposal instructions).

Contaminated packaging Empty containers should be taken to an approved waste handling site for

recycling or disposal. Since emptied containers may retain product residue,

follow label warnings even after container is emptied.

SECTION 14 TRANSPORT INFORMATION

UN Number Not hazardous for transport

Proper shipping name Not hazardous for transport

Transport hazard class(es)

ADR/RID/AND Not hazardous for transport
IMDG Not hazardous for transport
IATA/ICAO Not hazardous for transport
Packing Group Not hazardous for transport

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml)

Version No.: 02

Issue Date: March 25, 2016 Superseded No.: 01 **Environmental hazards** Marine Pollutant: Not available.

Special precautions for users

Not available. Subsidiary class **Emergency Number** Not available. ADR/RID labels Not available.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC code

Technical name Not available. Not available. Ship type Annex II Not available.

SECTION 15 REGULATORY INFORMATION

US federal regulations This material is not listed on the US TSCA 8(b) Inventory, therefore it may only

be used for TSCA exempt purposes such as R&D or drug use. Drugs, as that term is defined in the FFDC Act, in their solid final form (i.e. tablets or pills) are considered exempt under the criteria of the Federal OSHA Hazard

Communication Standard 29 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limits may be surpassed, they can

be considered hazardous.

OSHA GHS: GHS symbols in consumer packaged form are not required per OSHA 29 CFR 1910.1200(b)(5) and OSHA 29 CFR 1910.1200(b)(5)(iii).

SECTION 16 OTHER INFORMATION

Issue date March 25, 2016

Version # 02

TWi Pharmaceutical, Inc. cannot anticipate all conditions under which this Disclaimer

> information and its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and

experience currently available.

Megestrol Acetate Oral Suspension, 625mg/5ml (125mg/ml) Version No.: 02

Issue Date: March 25, 2016

Superseded No.: 01

Page 6 of 6